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To understand the mechanism by which peptide antigens are processed and presented to T 
cells, we examined the T-cell response to the I3-amino-acid peptide a-melanocyte-stimulating 
hormone (a-MSH). To determine the fine specificity of T-cell recognition, T cells specific for (Y- 
MSH, ,and genetically restricted by I-Abjd, were challenged with different a-MSH analogs and 
homologs. It was found that intact a-MSH, including the blocked amino and carboxy termini 
of the native molecule, was required for T-cell responsiveness. Antigen-presenting cells (APC) 
could be briefly pulsed with a-MSH and then present the (I-MSH antigenic determinant to T 
cells, indicating that the relevant antigen was retained by the APC. APC stimulatory capacity 
was dramatically reduced by aldehyde treatment of the APC, or by pulsing the APC with 01- 
MSH at low temperature. Efficient a-MSH pulsing was also impaired by treatment of the APC 
with the carboxyhc ionophore, monensin, but not by the lysosomotropic agents chloroquine 
and methylamine. In addition, isolated APC plasma membranes added to the T cells in the 
presence of soluble a-MSH were not stimulatory. However, plasma membranes isolated from 
APC that had been previously pulsed with n-MSH retained stimulatory activity for T-cell re- 
sponse!j. The only detectable o(-MSH contained in these pulsed APC membranes was in an acid- 
stable complex of higher molecular weight than native peptide. The amount of o-MSH detected 
in the cellular membrane fraction isolated by density gradient sedimentation was also reduced 
by treatments that reduced the APC stimulatory capacity, such as pulsing at low temperature or 
in the presence of monensin. Taken together, these results suggest that processing of (u-MSH is 
unlike that heretofore described for other peptide antigens and seems to involve APC handling 
to form the stimulatory moiety presented on the APC surface. o 1988 Academic press, IIIC. 
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INTRODUCTION 
Over the past several years significant advances have been made in defining the 
mechanism of antigen processing by antigen-presenting cells (APC)6 for presentation 
to T cells. First was the observation that native protein antigens needed to be catabo- 
lized to provide the appropriate antigenic determinants for T-cell responses ( 1,2). In 
these cases protein catabolism occurred by lysosomal proteolysis to provide antigenic 
derivative peptides. This event is necessarily dependent on protein antigen internal- 
ization by the APC, and hence is blocked by treatments that block endocytosis (glu- 
taraldehyde or paraformaldehyde) or lysosomal proteolysis (chloroquine or monen- 
sin) (1,2). In addition, it was found that the preformed derivative peptide when added 
to APC did not require internalization and could be presented by fixed cells. The lack 
of a requirement for peptide antigen internalization was shown more elegantly by 
demonstrating that planar membranes containing immunoaffinity-purified Ia anti- 
gen could present the antigenic peptide to T cells (3). These experiments suggested 
that peptide and Ia were all that was required for antigen presentation, and formally 
introduced the possibility that antigenic peptides may bind solely to Ia molecules to 
create the neoantigenic determinant recognized by T cells. Indeed, recent evidence 
using equilibrium dialysis supports this proposal by showing that a small fraction of 
the Ia molecules in a purified Ia preparation binds peptide antigens with relatively 
low affinity (4, 5). 
The latter results showing peptide antigen binding to Ia provides the long-antici- 
pated result that the T-cell receptor binds a neoantigenic determinant comprised of 
elements from both Ia and foreign antigen together. While it is therefore reasonably 
clear that an antigen-Ia complex is recognized by the T cell, the pathways that the 
antigen may take to eventually be bound by the Ia molecules are not clear. The sim- 
plest explanation is that exogenous peptide antigens bind directly to Ia on the APC 
surface to create the neoantigenic determinant. However, other reports suggest that 
the cellular reservoir of peptide antigen may involve an initial association with other 
non-Ia cellular structures (6-l 1). In addition, recent studies have shown that anti- 
genie proteins expressed only intracellularly are somehow processed to provide anti- 
genie peptides on the cell surface, presumably in association with MHC antigens ( 12, 
13). Based on these results, it has been suggested that antigenic peptides and MHC 
molecules become associated in an intracellular location and that this newly formed 
complex is transported to the cell surface to be recognized by T cells ( 14). 
To better characterize the mechanism(s) of peptide antigen handling by APC, we 
used the 13-amino acid-peptide antigen, cY-melanocyte-stimulating hormone (01- 
MSH), to investigate biochemical and functional aspects of APC processing. In this 
report we introduce this system and provide evidence suggesting that presentation of 
(-u-MSH represents a novel pathway of peptide processing. 
6 Abbreviations used: ACTH, adrenocorticotrophic hormone; APC, antigen-presenting cell; wMSH, 
a-melanocyte-stimulating hormone; IL-2, interleukin-2; Ia, I-region-associated antigen; SARS, specific 
antigen retention structures; FITC-fluoroscein isothiocyanate; FCS, fetal calf serum; HBSS, Hanks’ 
buffered saline solution; PBS, phosphate-buffered saline; PMSF, phenylmethylsulfonylfluoride; SDS, so- 
dium dodecyl sulfate; PPD, purified protein derivative: Con A, concanavalin A. 
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MATERIALS AND METHODS 
Animals. All mice used in these experiments were bred and maintained in the ani- 
mal facility at the University of Michigan Medical School. 
Peptide antigens. All synthetic peptides were purchased from Vega Biochemicals 
(Tucson, AZ). The primary structure of a-MSH (a derivative peptide comprising the 
first 13 residues of adrenocorticotrophic hormone, ACTH) is as follows: 
Fluorescein isothiocyanate (FITC)-a-MSH was made by incubation of (Y-MSH with 
a three-fold molar excess of FITC in 0.1 M carbonate buffer, pH 8.0, overnight at 
room temperature, and the free FITC was removed by chromatography over Sepha- 
dex G- 10 (Pharmacia Fine Chemicals, Piscataway, NJ) in phosphate-buffered saline, 
pH 7.2. Under these conditions only the Lys” can be conjugated. 
Cell lines. Mice were immunized with 100 pg of a-MSH in complete Freund’s 
adjuvant (Difco Laboratories, Detroit, MI); 10 days later the draining lymph nodes 
were removed and the immune T cells (2.5 X 106/ml) stimulated by culture with 8 
pg/ml of tx-MSH in RPM1 1640 medium (M. A. Bioproducts, Walkersville, MD) 
containing 300 pg/ml glutamine (KC Biological, Lenexa, KS), 5 X 1 Om5 A4 %-mercap- 
toethanol (Bio-Rad Laboratories, Richmond, CA), and 10% heat-inactivated fetal 
calf serum (FCS, Hyclone Laboratories, Logan, UT) for 3 days at 37°C in 5% CO2 
in air. The blast cells were harvested by centrifugation on Ficoll-Hypaque (Sigma 
Chemical Co., St. Louis, MO) and either subcloned by limiting dilution in microtiter 
wells containing a-MSH and fresh irradiated syngeneic spleen cells, or expanded and 
fused with BW5 147 cells by established procedures ( 15, 16). Hybridomas were 
screened for production of interleukin-2 (IL-2) specifically upon stimulation with (Y- 
MSH and (C57BL/6 X BALB/C) F, spleen cells, and positive hybrids subcloned to 
produce stable lines, of which 27E 11 is representative. 
Since all T cell responses to a-MSH were genetically restricted by I-Ab’d, LB27.4 
cells, a hybrid B-cell line expressing Iabld (17), were used as APC in most experiments, 
and were a generous gift from Dr. D. Shapiro of the University of Michigan Medical 
School. The monoclonal antibodies were obtained as culture supernatant fluids from 
hybridomas obtained from the American Type Culture Collection (Rockville, MD) 
and include 10.2.16, anti-IAk (18); MKD6, anti-IAd (16); and M5/114.15.2, anti- 
IAb,d,qIEd,L’ ( 19). 
APC twatment. APC were pulsed by incubation with 200 pg/ml of cu-MSH for 2 
hr (or overnight in some experiments) at 37°C (or 4°C in some experiments) in serum- 
free medium, then washed three times in Hanks’ buffered saline solution (HBSS, KC 
Biological) to remove free peptide. In some experiments using monensin, chloro- 
quine, and methylamine, the cells were preincubated with the agent at the concentra- 
tions indicated in the table 30 min before adding a-MSH, and left in culture for the 2- 
hr pulse. For glutaraldehyde fixation, cells were washed in phosphate-buffered saline 
(PBS, pH 7.2) and treated by mixing for 15 set with the indicated concentration of 
glutaraldehyde in PBS. The reaction was terminated by adding excess PBS containing 
0.1% glycine (Sigma) and the cells were washed three times before being used. 
Preparation ofplasma membranes. Antigen-pulsed or unpulsed LB27.4 cells were 
washed three times in HBSS and resuspended in HBSS containing 1 pg/ml of phenyl- 
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methylsulfonylfluoride (PMSF, Sigma); then the cells were disrupted in a cell dis- 
rupter (Stansted Fluid Power Ltd., Essex, England) using an aperture setting that 
sheared only the plasma membranes from the surface of the cells while leaving the 
nucleus and much of the cytoplasm intact, according to the method of Crumpton 
and Snary (20). The sheared cells were centrifuged at 4508 for 10 min at 4°C to re- 
move nuclei and intact cells; then the supernantant fluid was centrifuged at 3650g 
for 15 min at 4°C to pellet subcellular organelles. The resultant supernatant fluid was 
centrifuged at 3 1 ,OOOg for 40 min, and the resultant crude plasma membrane pellet 
was resuspended in sterile PBS and immediately used for addition to culture or stored 
at -70°C. 
To determine the cellular location of the radioactive peptide, LB27.4 cells were 
pulsed with 10 PCi of ‘*‘I-WMSH for 2 hr at 37°C in 4 ml of RPM1 1640 containing 
10 pg/ml of cycloheximide. In experiments examining the effects of inhibitors, 50 
PMchloroquine or monensin was added 30 min prior to the addition of peptide. The 
pulsed cells were washed three times in HBSS to remove non-cell-associated peptide, 
and then resuspended in ice-cold HBSS containing 10 pg/ml of PMSF. The cells were 
disrupted by two passes through the Stansted cell disrupter set at an aperture that 
sheared all of the outer membranes and cytoplasm from the cells. Nuclei were re- 
moved by centrifugation at 450g for 10 min at 4°C. The postnuclear cell lysate was 
run over a Percoll gradient according to the method of Merion and Poretz (21). 
Briefly, the cell lysate (12 ml) was layered over a 30% Percoll (Pharmacia) solution 
(22 ml) that had previously been layered over 3 ml of a 60% sucrose preparation. The 
tubes were centrifuged in a Beckman Ti55.2 fixed-angle rotor at 40,OOOg for 60 min 
at 4°C. Fractions (1 ml) were collected from the bottom and the ‘*‘I cpm in each 
fraction determined in a gamma counter. Density standard beads (Pharmacia) were 
added to each tube to determine the density assignments of the various fractions. 
Location of the plasma membrane fraction was determined from lysate of cells that 
were pulsed for 30 min at 4°C with ‘251-concanavalin A (Con A, New England 
Nuclear, Boston, MA) and washed to leave only plasma membrane-bound lectin. It 
should be pointed out that the plasma membrane fraction identified in this manner 
also contains Golgi and lysosomal membranes (2 1) and is therefore referred to as the 
cellular membrane fraction in the remainder of this report. 
Chromatographic analysis of radioactive a-MSH. a-MSH was radioiodinated with 
‘25I using Iodo-beads according to an established protocol (Bio-Rad) to yield ‘*$LY- 
MSH with sp act of 5.3 to 6.1 pCi/pg in various preparations. Intact cells or isolated 
plasma membranes were incubated at 37°C for 4 hr, or overnight in some experi- 
ments, and then the cells washed and solubilized in 0.5% Nonidet P-40 as described 
elsewhere (6). The soluble preparations were made to 10% acetic acid and chromato- 
graphed over a 2.5 X 50-cm column of Sephadex G-25 Superfine (Pharmacia), and 
the 1251 cpm of each collected fraction determined as before (6). 
T-Cell stimulation culture and assay for IL-2 production. cr-MSH-specific T cells 
(2 X 105/well) were cultured with lo5 LB27.4 cells, or lo6 spleen cells with or without 
different concentrations of peptide antigen as indicated under Results. After 20 hr 
of culture the supernatant fluids were removed and assayed for IL-2 with the IL-2- 
dependent HT-2 cell line (a generous gift from Dr. E. Shevach, NIH) as described 
elsewhere (16). The greatest dilution of supematant fluid maintaining more than 90% 
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HT-2 viability was the end point scored, and the reciprocal of this dilution is ex- 
pressed as IL-2 units per ml. 
RESULTS 
Specificity of T-Cell Responses to a-MSH 
In our previous work we have studied the cellular immune response to several 
different peptide systems to better understand the molecular basis for antigen presen- 
tation to T cells. Most of this work has used guinea pigs because of the ease of generat- 
ing antipeptide cellular responses in that species. However, the guinea pig model is 
limited in not having available homogeneous T-cell and APC lines necessary to better 
define the biochemical basis of antigen recognition. It was therefore necessary to es- 
tablish a peptide antigen system in mice to better analyze antigen processing and 
presentation using homogeneous cell lines. We chose a-MSH as the model antigen for 
several reasons: synthetic a-MSH could be purchased at a reasonable cost; synthetic 
analogs and homologs were also available; the peptide could be radiolabeled; it was 
relatively hydrophilic; and it was potentially interesting with regard to the response 
of the immune system to neuropeptides. In exploratory studies a-MSH was tested for 
antigenicity by injection into mice of different H-2 haplotypes (b, d, k, and b X d F,). 
By in vitro lymph node lymphocyte proliferative responses, it was found that only (b 
X d) F, mice were responders to a-MSH, and the other strains tested were unrespon- 
sive by this criterion. T cells from cr-MSH-immunized F, mice were also hybridized 
and a-MSH-specific IL-2-producing hybridomas identified: one of these with repre- 
sentative specificities, 27E 11, was used for further studies as described in this report. 
The peptide and MHC specificities of the 27Ell T-cell response are summarized 
in Table 1. It is clear that the response to a-MSH requires the intact native peptide; 
shortened or lengthened peptides do not provide the relevant antigenic determinant. 
In addition, the substitution of Nle4 greatly reduces antigenicity, which is further 
reduced by the additional substitution of D-Phe7, and antigenicity is destroyed by 
modifying Lys’ ‘. This fine specificity of 27E 11 is the same as found for polyclonal T- 
cell responses to a-MSH (data not shown). Another interesting feature of cu-MSH 
antigenicity is that both termini are blocked in the native molecule, and that unblock- 
ing either end greatly reduces antigenicity for 27E 11 responses (Table 1, lines 4 and 
5). This, together with the requirement for intact a-MSH for antigenicity, strongly 
suggests that the relevant antigenic determinant is only present on unaltered native 
a-MSH. This is an important consideration, as will become evident later. Also shown 
in Table 1 is that the response of 27E 11 is genetically restricted by a recombinant Ia 
molecule, I-Abld, as found for all T-cell responses to this antigen, and is inhibited by 
antibodies directed against the A,d chain. 
Cellular Fate of a-MSH 
To ensure that the (u-MSH system was suitable for examining antigen presentation 
by APC, we first determined that cY-MSH-pulsed APC (LB27.4 cells or H-2b’d spleen 
cells) stimulated T cells (Table 1). It is clear that cY-MSH-pulsed cells are highly stimu- 
latory, but the IL-2 titers are often slightly less than those obtained from cultures with 
soluble cu-MSH continuously present, as can be seen in some of the following tables. 
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TABLE I 
Fine Specificity of T-Cell Responses to ol-MSH 
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Note. The relative IL-2 responses shown are a summary of a number of different experiments compiled 
into a single table for ease of presentation. While similar responses were observed for both ol-MSH-specific 
T-cell clones and hybridomas, the results depicted are for the T-cell hybridoma 27E 11 (2 X lo5 cells/well) 
stimulated with peptide with either the LB27.4 cell line (10’ cells/well) or spleen cells ( lo6 cells/well) as 
indicated. For antigen specificity, each peptide was tested in serial dilutions with the highest concentration 
being 20 pg/well. The response of 27E 11 is at its peak at around 2 fig/well, and those weak responses shown 
for the peptide analogs were observed only at 20 &well, In some experiments APC were pulsed with a- 
MSH for 2 to 18 hr in serum-free medium and washed to remove unbound peptide as described under 
Materials and Methods. All monoclonal anti-la antibodies (anti-IAk, 10.2.16; anti-IAd, MKD6; and anti- 
IAb*d,q IEd,k, M5/114.15.2) were added at a 10% final volume of antibody-containing culture supematant 
fluids.‘The IL-2 titers were scored visually by the highest dilution that maintained viability of the IL-2- 
dependent cell line HT-2. The relative responses are scored as follows: +++, IL-2 titers of 640-2560; ++, 
IL-2 titers of 160-320; +, IL-2 titers 40-80; f, IL-2 titers of 20; -, IL-2 titers of ~20. 
To examine the cellular fate of the peptide the APC (LB27.4 cells) were incubated 
with radiolabeled a-MSH and chromatographed to resolve the cell-associated radio- 
activity. As shown in Fig. 1 A, most of the LB27.4 cell-associated (Y-MSH is degraded 
to fragments migrating at fractions 60-65 (and also at fractions 75-80 in some experi- 
ments, e.g., as shown in Fig. 2); a small amount of native a-MSH running at fractions 
52-57 is detectable in some experiments after a 4-hr incubation. There is also a sig- 
nificant amount of a-MSH (5 to 15% of the total cell-associated amount) migrating 
with an apparent molecular weight greater than the native peptide in the void volume 
of the column at positions 23-25 (Peak A), similar to that previously observed with 
other peptides incubated with guinea pig cells (6). It should be pointed out that this 
Peak A material does not necessarily refer to a single molecular species, since many 
cellular proteins are contained in the void volume. As we have shown before, forma- 












FIG. 1. Formation of a higher molecular weight form of a-MSH by LB27.4 cells and plasma membranes. 
LB27.4 cells (5 X 106, panel A) or isolated plasma membranes (80 X lo6 cell equivalents, panel B) were 
incubated with ‘251-~-MSH (5 &/ml) in serum-free medium for 4 hr at 37°C and the cells were washed 
to remove non-cell-associated peptide. Both the cells and membranes were solubilized and the soluble 
material was made to 10% acetic acid and chromatographed on Sephadex G-25, as described under Materi- 
als and Methods. The void volume ofthe column is around fraction 25 (shown by migration of cytochrome 
C as indicated by the bar), and native a-MSH migrates at approximately fraction 55. Note that there is a 
scale difference between panels A and B and that the migration of a-MSH is the same in both experiments. 
The material eluting with the void volume is called Peak A. 
tion of these Peak A complexes is peptide-specific, and these complexes are not pro- 
duced by all cell types, thereby ruling out that the Peak A material represents nonspe- 
cific trapping under the conditions used to run the column (6, 22). Indeed, acidic 
conditions were employed to enhance peptide solubility and avoid aggregation. 
These latter results indicate that the a-MSH contained in Peak A may represent 
peptide stably bound to some higher molecular weight cellular component. To deter- 
mine whether these binding structures were located in the membrane, plasma mem- 
branes were isolated from LB27.4 cells and incubated with radiolabeled a-MSH. As 
we found before for other peptide antigens (6,7), complexes containing cr-MSH can 
be detected in association with the plasma membrane, as shown in Fig. 1B. It is also 
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FIG. 2. The nature of a-MSH contained in the Peak A complex. LB27.4 cells (5 X 106) were incubated 
with ‘251-ol-MSH as described in the legend for Fig. 1. The ol-MSH-containing Peak A complex was isolated 
by chromatography on Sephadex G-25 as before and an aliquot used to determine the cpm of each fraction 
(panel A). The fractions containing the Peak A (25-27) were pooled, lyophilized, then redissolved in buffer 
containing 1% SDS, boiled for 5 min, and rechromatographed on Sephadex G-25 as before (panel B). Note 
that there is a scale difference between panels A and B and that CY-MSH migrates at a similar position in 
both experiments. 
apparent by the presence of a large peak at positions 65-70 that the membrane prepa- 
rations contain proteases that can degrade (Y-MSH. 
As shown in Table 1, it appears that the intact native CX-MSH peptide is required 
for antigenicity. To determine if the radioactivity in the Peak A material was still 
associated with some form of or-MSH, the Peak A made by LB27.4 cells was isolated 
by chromatography on Sephadex G-25, as shown in Fig. 2A. In this particular experi- 
ment the degraded peptide migrated more slowly than usual, but this did not influ- 
ence the isolation of the complex that migrated in the void volume at positions 24- 
27. The isolated Peak A was then boiled in sodium dodecyl sulfate (SDS) to dissociate 
the peptide component and rechromatographed to identify the size of the CX-MSH 
contained in the complex. As shown in Fig. 2B, all of the peptide was released from 
the complex upon boiling in SDS, suggesting a noncovalent association in this case, 
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TABLE 2 
T-Cell Stimulation by Plasma Membranes from cY-MSH-Pulsed APC 
IL-2 (Units/ml) 
Additions to culture Expt 1 Expt 2 
LB27.4 cells <20 <20 
LB27.4 cells + 2 pg soluble ol-MSH 1280 1280 
LB27.4 cells + anti-IAd ND 80 
LB27.4 cells pulsed with o(-MSH 320 ND 
LB27.4 plasma membranes 120 <20 
LB27.4 plasma membranes + 2 fig soluble a-MSH <20 <20 
Plasma membranes from cy-MSH-pulsed LB27.4 cells 40 160 
Plasma membranes from cu-MSH-pulsed LB27.4 cells + anti-IAd ND <20 
Note. T cells (2 X lo5 27Ell) were cultured with lo5 LB27.4 cells with or without a-MSH and MKD6 
anti-Ia (10% fmal volume of antibody-containing supematant fluid) as indicated in the table. Plasma mem- 
branes were isolated from unpulsed LB27.4 cells or LB27.4 cells that had been pulsed overnight with 150 
fig/ml (Expt 1) or 200 pg/ml (Expt 2) of (u-MSH and washed to remove non-cell-associated peptide. The 
isolated plasma membrane preparations were added to 27E I 1 T cells in varying concentrations and the 
results are shown for 6 X lo6 cell equivalents. Other experiments (not shown) using soluble a-MSH at 
concentrations up to 20 fig with unpulsed LB membranes failed to cause T-cell stimulation. The IL-2 units 
were determined as described under Materials and Methods. ND, not determined. 
and migrated as a single peak in a position similar to that of native ol-MSH. Thus, 
the Peak A complex contains a form of a-MSH that appears homogeneous and does 
not contain a variety of degraded peptide fragments. Although the migration of the 
released peptide migrates in a position similar to that of native (r-MSH, these condi- 
tions of fractionation may not discriminate subtle modifications of the released pep- 
tide. Of interest, we have found with other peptide antigens that some of the Peak A 
complex ( 10 to 50%) is resistant to repeated boiling in SDS, indicating covalent bond- 
ing (6), which may involve the carboxyl terminus (7, S. Jun, unpublished obser- 
vations). 
T-Cell Stimulation by Isolated APC Plasma Membranes 
Since in most peptide antigen systems no antigen processing is apparent, T cells 
can be directly stimulated by peptide antigen in the presence of Ia-containing mem- 
branes. To determine if this were also true in the a-MSH system, membranes were 
isolated from LB27.4 cells and examined for stimulation of 27Ell T cells in the 
presence of cr-MSH. To our surprise, APC membranes alone failed to stimulate in 
the presence of peptide (Table 2). Thus, presentation of c~-MSH is apparently differ- 
ent than in other peptide antigen systems examined to date. Since we knew that (Y- 
MSH-pulsed LB27.4 cells were stimulatory, which at some point involves recognition 
of antigen on the APC surface, we decided to isolate plasma membranes from LB27.4 
cells that had been previously pulsed with (Y-MSH, and therefore likely to contain the 
relevant antigen. As shown in Table 2, plasma membranes isolated from a-MSH- 
pulsed LB27.4 cells directly stimulated the 27Ell T cells, which were inhibited by 
anti-IAd antibodies, whereas membranes from unpulsed cells added with soluble (Y- 
396 THOMAS ET AL. 
--- - 
SO0 - \ 
400 - 
A alpha-MSH 
300 - 1 
200 - 
100 - 
FIG. 3. The nature of (u-MSH contained in the plasma membranes of or-MSH-pulsed LB27.4 cells. 
LB27.4 cells (40 X 106) were incubated overnight with ‘251-a-MSH in parallel with the cells used in Table 
2, Experiment 2. The plasma membranes were isolated from the pulsed cells and solubilized, and the 
soluble material was chromatographed on Sephadex G-25 as before. All of the ‘25I cpm were detected in 
the soluble fraction of the membrane preparation. 
MSH were nonstimulatory. The fact that membranes from unpulsed cells were rou- 
tinely nonstimulatory in the presence of soluble peptide rules against the stimulation 
with membranes from antigen-pulsed cells being due to a few contaminating viable 
cells, which would further be resistant to freeze-thawing. Though readily apparent, 
the stimulation by membranes from pulsed cells was significantly less than that by 
intact pulsed cells from which the membranes were derived on a cell-equivalent basis 
(320 titer for lo5 pulsed intact cells, versus titers of 40 to 160 for 6 X lo6 cell equiva- 
lents of membranes). Much of this difference is probably due to the fact that the 
membrane isolation procedure is not 100% efficient, and that at least half of the mem- 
branes are present as nonfunctional inside-out vesicles. 
To determine in what form (r-MSH existed in stimulatory membranes from pulsed 
APC, LB27.4 cells were incubated with radiolabeled ol-MSH under conditions identi- 
cal to those in the functional experiment described above, and the plasma mem- 
branes of these cells were prepared at the same time as the pulsed membranes used 
for functional assessment (Table 2, Experiment 2). The isolated membranes contain- 
ing the radiolabeled (r-MSH were solubilized (all radioactivity was soluble) and chro- 
matographed as before. As shown in Fig. 3, all of the membrane-associated a-MSH 
was associated with a higher molecular weight moiety, and there was no detectable 
free peptide. The apparent split in the Peak A observed in this particular experiment 
is due to slightly lower cpm in one fraction, which we do not consider to be significant 
and was not observed in many other experiments. 
Evidence for a-MSH Processing by APC 
One explanation for the results with unpulsed and a-MSH-pulsed membranes de- 
scribed above is that the creation of a stimulatory form of (r-MSH requires cellular 
processing. In most other systems with protein antigens, this involves antigen inter- 
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TABLE 3 
Effect of Aldehyde Fixation on a-MSH Presentation 
APC treatment T cells IL-2 (Units/ml) 
Untreated 27EI 1 <20 
Untreated +5 fig soluble c+MSH 27El I 640 
0.1% Glutaraldehyde treated 27Ell <20 
0.1% Glutaraldehyde treated +5 rg soluble (u-MSH 27Ell 40 
Untreated 8B2 <20 
Untreated + 10 pg soluble PPD 8B2 640 
0.1% Glutaraldehyde treated + 10 fig soluble PPD 8B2 640 
Untreated or glutaraldehyde treated LB 27.4 cells were added to culture with 27E I 1 (ol-MSH/IAbId spe- 
cific) or 8B2 (PPD/IAd specific) with soluble antigen as indicated in the Table. Representative IL-2 titers 
from one experiment are shown, and similar results have been obtained in six other experiments. 
nalization (blocked by aldehyde fixation) and catabolism by lysosomal enzymes 
(blocked by chloroquine and monensin). To test this, a variety of treatments were 
used that either inhibited cellular internalization or prevented intracellular transport 
and acidification, as have been used by many others examining antigen processing 
(1, 2). First, glutaraldehyde-treated LB27.4 cells showed a greatly reduced ability to 
present wMSH when compared to untreated APC (Table 3). However, these same 
fixed APC were able to efficiently present the antigen purified protein derivative 
(PPD) to PPD-specific T cells. In previous studies we have found that PPD did not 
require APC internalization and intracellular processing for presentation to T cells 
by A20 and LB27.4 cells (16). These findings suggest that the most efficient presenta- 
tion of (w-MSH requires peptide internalization by the APC. Consistent with this is 
that pulsing the APC with wMSH at 4°C which also impairs membrane mobility 
and antigen internalization, is much less efficient than pulsing at 37°C (IL-2 titers of 
~20-40 at 4°C versus 160-320 at 37°C). 
For most protein antigens, cellular internalization is required for lysosomal degra- 
dation of the protein to form antigenic peptides. This event can be blocked by agents 
(chloroquine, methylamine, and monensin) that interfere with intracellular 
trafficking and lysosomal proteolysis. This internalization-proteolysis step is not 
needed for antigenic peptides thus far described ( l-5) and, indeed, seemed unlikely 
to be involved in (Y-MSH processing as discussed above. It was therefore not surpris- 
ing that chloroquine and methylamine had no effect on the antigenicity of a-MSH 
pulsed LB27.4 cells, as shown in Table 4. In our hands, treatment with these agents 
at similar concentrations efficiently blocks processing of protein antigens by some 
APC (15, unpublished observations). However, we were surprised to find that monen- 
sin at 10 PM or greater dramatically reduced (u-MSH stimulation when present dur- 
ing the antigen pulse. LB27.4 cells treated with monensin and cultured to allow recov- 
ery presented LU-MSH efficiently, suggesting that monensin inhibition is not generally 
toxic (data not shown). 
To determine the reason for the reduction in stimulatory capacity of APC pulsed 
with a-MSH at 4°C or in the presence of monensin, we examined the cellular com- 
partmentalization of radiolabeled a-MSH under these conditions using density gradi- 
398 THOMAS ET AL. 
TABLE 4 
Effect of Inhibitors on ol-MSH Presentation 
APC treatment IL-2 (Units/ml) 
Unpulsed <20 
oc-MSH-pulsed with no inhibitor 160 
+Monensin, 3 PM 160 
+Monensin, 30 PM 20 
+Monensin, 100 FM <20 
+Chloroquine, 3 &4 320 
+Chloroquine, 30 PM 320 
+Chloroquine, 100 PLM 160 
+Chloroquine, 300 pkr 160 
tMethylamine, 10 mA4 160 
+Methylamine, 30 m&f 160 
+Methylamine, 100 mM 160 
Note. Representative experiments are shown for the effects of the various inhibitors of a-MSH pulsing 
of LB27.4 cells treated as described under Materials and Methods. Unpulsed or ol-MSH-pulsed (150 fig/ 
ml) and treated LB27.4 cells ( 105) were added to 2 X lo5 27E11 T cells for overnight culture, and the IL-2 
titers determined as before. 
ent separation of the cellular components. To calibrate the Percoll gradient to identify 
the membrane fractions, LB cells were incubated with 1251-Con A, which binds solely 
to the plasma membranes under these conditions, and the disrupted cell lysate sedi- 
mented over the self-forming Percoll gradient (Fig. 4A). As can be seen, the mem- 
brane-bound Con A sedimented with an apparent density of 1.045, which was highly 
reproducible from experiment to experiment. Unbound soluble Con A migrated at 
fractions 22-30, which is representative of soluble material with lower density (data 
not shown). Although the membrane fraction isolated by this procedure contains 
plasma membranes, also included are Golgi and some lysosomes, and it is therefore 
only representative of total cellular membrane material. However, this fractionation 
allowed us to determine the amount of membrane-bound and free antigen contained 
in the cell. We found that the total cell-associated ‘251-a-MSH following a 2- or 4-hr 
pulse at 37°C with or without monensin, or at 4°C was similar, but that the cellular 
compartmentalization was different (Figs. 4B and 4C). Thus, the amount of mem- 
brane-associated (u-MSH was reduced by 40-50% at 4°C and by 60-70% in the pres- 
ence of monensin when compared to controls. In other experiments it was found that 
monensin treatment of the cells after antigen pulsing did not reduce the amount of 
membrane-associated a-MSH, and chloroquine treatment during the pulse also 
failed to reduce the amount of membrane-associated (Y-MSH (data not shown). Thus, 
there seems to be a correlation between the amount of membrane-associated (Y-MSH 
and the APC stimulatory capacity, and treatments that reduce stimulation likewise 
reduce the amount of membrane-associated antigen. 
What Is the Peak A Complex? 
Since the only detectable membrane-bound form of a-MSH evident by our proce- 
dures was associated with a higher molecular weight form designated as Peak A, it 
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was important to establish whether the cellular component to which CY-MSH was 
bound was Ia antigen. In one approach, we attempted to immunoprecipitate the Peak 
A from LB cell lysates following pulsing with ‘?-ol-MSH, as before, with the mono- 
clonal anti-Ia antibody M5/ 114.15.2. Subsequent chromatography over Sephadex G- 
25 showed that all the 1251 cpm remained as Peak A in the cell lysate and that no cpm 
were removed by the anti-Ia antibody precipitation. However, it was possible that 
once Ia bound peptide, it was no longer reactive with anti-Ia antibody. For this rea- 
son, we determined whether Peak A would bind to Lens culinaris lectin, which binds 
Ia glycoproteins through mannose-containing carbohydrates, and would not likely 
be influenced by peptide binding. Again it was found that Peak A failed to bind insol- 
ubilized lectin, suggesting that if it is a glycoprotein it may not contain mannose. 
Both of these properties of Peak A formed with cu-MSH are similar to those we found 
with guinea pig cells pulsed with other peptides (6). In addition, Peak A can be formed 
with a-MSH by both Ia-expressing and Ia-negative cells. Peak A derived from both 
of these cell types seems to be comprised of the same major acidic component(s) as 
determined by isoelectric focusing (22, unpublished results). Taken together, these 
results indicate that the majority of Peak A is not Ia-bound peptide, although final 
confirmation of this awaits further structural characterization. 
DISCUSSION 
The primary reason for studying murine T-cell responses to (u-MSH was to estab- 
lish a system to more carefully examine the events associated with antigen processing. 
In this report we present two observations on cellular processing of the peptide anti- 
gen (u-MSH for T-cell responses that are of importance for mechanisms of antigen 
presentation. The first is that the only detectable form of a-MSH contained in isolated 
antigen-pulsed APC membranes that are directly stimulatory for T cells is as a higher 
molecular weight complex, and no detectable free peptide. The second observation 
is that in this system a-MSH appears to require cellular processing to form the stimu- 
latory moiety. 
There seem to be several pathways by which foreign antigens may become associ- 
ated with Ia antigens for T-cell recognition. In some instances peptide antigens may 
directly bind to Ia molecules, as recent evidence suggests (4, 5). In other systems, 
peptides may initially be retained by the APC through interactions with membrane 
lipids (10, 11) or by association with specific antigen retention structures (SARS) (6- 
8), to provide the cellular reservoir of antigen that subsequently becomes associated 
with Ia. In yet another system, the peptide antigen human fibrinopeptide B is recog- 
nized by a T-cell hybridoma only when added in soluble form, but not when bound 
by APC (23). In addition, the processing pathway varies for different APC types, in 
some instances to form the very same antigenic determinant recognized by T 
cells ( 16). 
The presentation of o+MSH described herein seems to provide another pathway 
for peptide antigen processing that is different than that for peptide antigen systems 
described at the present time. In this system, APC handling of cu-MSH seems to in- 
volve cellular processing to form the stimulatory form. The evidence for this is as 
follows: (a) inhibition of a-MSH processing by glutaraldehyde treatment; (b) ineffec- 
tive antigen pulsing at low temperature; (c) inability to process a-MSH in the pres- 
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FIG. 4. Cellular compartmentalization of o(-MSH. LB27.4 cells (20 X 106) were incubated with ‘*51-Con 
A at 4°C for 30 mitt, and after washing away the unbound Con A, the cells were disrupted and the lysate 
sedimented over a Percoll gradient as described under Materials and Methods. In panel A is shown the 
density distribution in the gradient and the migration of the membrane-associated “‘I-Con A. In panels B 
and C are shown results of sedimentation of disrupted cell lysates from LB27.4 cells incubated for 2 hr at 
37 or 4°C with ‘?-a-MSH (Panel B) or at 37°C in the presence or absence of 50 PM monensin (Panel C). 
The membrane fraction can be seen to migrate at a density of 1.045 when compared to internal standards 
in each experiment, and more soluble material sediments with density of less than 1.025. 
ence of monensin; and (d) the failure of Ia-bearing membranes from unpulsed APC 
to stimulate in the presence of soluble ol-MSH, compared to the direct stimulatory 
capacity of isolated membranes from a-MSH-pulsed APC. The most prevalent expla- 
nation for the failure of aldehyde-treated APC to process antigen is that fixation pre- 
vents antigen internalization (1,2). However, this generally does not apply to peptide 
antigens that are presented efficiently by fixed APC. Thus, the marginal capacity of 
fixed APC to present (r-MSH is unique for peptide antigens investigated thus far. This 
could be interpreted to indicate that (Y-MSH must be internalized to be stimulatory, 
or that some membrane reorganization is required to construct the stimulatory CY- 
MSH-Ia moiety which is interfered with by aldehyde treatment. In this latter case, 
though, any postulated membrane reorganization must need the intact cell, since 
isolated membranes from APC are not stimulatory; once the stimulatory moiety is 
formed there is no further need for the intact cell since plasma membranes from LY- 
MSH-pulsed APC are directly stimulatory. Such a mechanism is difficult to envision, 
and we therefore favor the former possibility that (Y-MSH requires internalization to 
form the stimulatory moiety. 
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If formation of the c+MSH stimulatory moiety indeed requires cellular internaliza- 
tion, it is important to establish what processing events occur inside the cell. Again, 
for most protein antigens one internal event occurs in an acidic compartment, which 
has been interpreted to be lysosomal catabolism. Agents that raise the pH in these 
compartments, such as chloroquine, thus block antigen processing by preventing pro- 
teolysis (2, 16). However, such treatment has no effect on the processing and presenta- 
tion of a-MSH. This suggests that lysosomal catabolism of (u-MSH is not required to 
form the stimulatory moiety. This is consistent with the fact that intact unaltered cy- 
MSH is needed to provide the antigenic determinant recognized by T cells; no cy- 
MSH fragment is antigenic. Therefore, it is unlikely that processing of LU-MSH in- 
volves catabolism to a smaller antigenic fragment. However, it is possible that the 
peptide undergoes some other nonproteolytic modification that is required to create 
an altered form of a-MSH that actually provides the determinant recognized by T 
cells, e.g., phophorylation. 
Irrespective of the precise mechanisms involved in APC handling of a-MSH, it 
would seem that at least some of these may be involved in association of the peptide 
with the APC membrane fraction. Thus, those treatments that reduce the stimulatory 
capacity through actions at the time of antigen exposure (a-MSH pulsing at 4°C 
and in the presence of monensin) also reduce the amount of detectable membrane- 
associated (-u-MSH. Since the overall amount of a-MSH associated with the cells un- 
der these different conditions was similar, these treatments must have some effect on 
a-MSH handling other than just reducing the amount of cell-associated antigen. One 
possibility is that the relevant or-MSH enters the APC by endocytosis of soluble pep- 
tide (though not blocked by cytochalasin B, unpublished observations) and becomes 
membrane-associated at some subsequent step. This process would be reduced at 
lower temperatures and potentially also by monensin. Alternatively, the peptide may 
bind to some rapidly cycling binding structure that is itself membrane-bound; cycling 
to an exposed location would also be blocked by low temperature and possibly by 
monensin as well. Potentially, monensin may block formation of the membrane- 
bound ol-MSH by other effects on the cell, such as intracellular transport or effects on 
the Golgi complex (24) or by interference with other aspects of a-MSH modification. 
The correlation between the amount of a-MSH associated with APC membranes 
and their T-cell stimulatory capacity is perhaps not surprising, since it is generally 
accepted that most T cells recognize antigen on the APC membrane in combination 
with MHC antigens. In this regard, the only membrane-associated form of a-MSH 
we could detect was as a higher molecular weight complex. It would be anticipated 
that this complex contains c+MSH bound to Ia to provide the neoantigenic determi- 
nant that is actually recognized by the T cell. However, as yet we have been unable to 
demonstrate peptide bound to Ia by our detection procedures. Thus, the correlation 
between stimulatory capacity and membrane-associated cu-MSH could have several 
explanations. One possibility is that a small undetectable amount of the Peak A com- 
plex contains a-MSH bound to Ia, and the formation of this moiety is subject to 
the same influences as formation of complexes with the more predominant non-Ia 
constituents. Alternatively, cu-MSH may not be bound to Ia at this point and is simply 
retained by non-Ia structures for subsequent association with Ia. Resolution of these 
possibilities awaits further characterization of the products contained in the Peak A 
complex and their relative contribution to immune responses. 
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